A5009957675- Sarcoma Diagnosis and Treatment
- Cardiac tumors and thrombi
- Soft tissue tumor case studies
- Vascular Tumors and Angiosarcomas
- CAR-T cell therapy research
- Gastrointestinal Tumor Research and Treatment
- Lymphoma Diagnosis and Treatment
- Nuclear Structure and Function
- Tumors and Oncological Cases
- Neurofibromatosis and Schwannoma Cases
- Virus-based gene therapy research
- Genomics and Chromatin Dynamics
- Angiogenesis and VEGF in Cancer
- RNA Interference and Gene Delivery
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Oral and Maxillofacial Pathology
- Molecular Biology Techniques and Applications
- Microtubule and mitosis dynamics
- Cancer Genomics and Diagnostics
- Protein Degradation and Inhibitors
- Cancer Diagnosis and Treatment
- Electric Motor Design and Analysis
- Cancer Immunotherapy and Biomarkers
- Chronic Myeloid Leukemia Treatments
Universidad Autónoma de Madrid
2022-2025
Hospital Universitario Fundación Jiménez Díaz
2022-2025
Hospital Universitario Virgen del Rocío
2018-2023
Centro Hospitalar de Entre o Douro e Vouga E.P.E.
2023
Universidad de Sevilla
2017-2021
Instituto de Biomedicina de Sevilla
2017-2021
National Research Council
2020
Centro de Investigación del Cáncer
2016-2018
Universidad de Salamanca
2015-2018
Consejo Superior de Investigaciones Científicas
2015-2016
Background Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity PD-1 inhibitors. A potential strategy convert a cold into an inflamed microenvironment lies on combination therapy. As tumor angiogenesis promotes immunosuppression, we designed phase Ib/II trial test double inhibition (sunitinib) and PD-1/PD-L1 axis (nivolumab). Methods This single-arm, enrolled adult patients with selected subtypes sarcoma. Phase Ib established two dose...
All types of DNA damage cause a local alteration and relaxation chromatin structure. Sensing reacting to this initial is necessary trigger for any type response (DDR). In context, kinases are likely candidates participate in detection reaction locally altered as consequence and, thus, initiate the appropriate cellular response. work, we demonstrate that VRK1 nucleosomal kinase its depletion causes loss histones H3 H4 acetylation, which required relaxation, both basal conditions after damage,...
11506 Background: Dedifferentiated chondrosarcoma (DDCS) is a rare aggressive CS subtype with dismal prognosis and no standard of care systemic therapy. For those advanced, metastatic disease, retrospective chemotherapy studies demonstrate short-term median progression-free survival (PFS) around 3 to 5.5 months. Benefit from checkpoint tyrosine kinase inhibitors has been reported, however clinical trial data scarce, endpoints are not well defined, thus benchmarking outcomes challenging. The...
Regulation of cell division requires the integration signals implicated in chromatin reorganization and coordination its sequential changes mitosis. Vaccinia-related kinase 1 (VRK1) Aurora B (AURKB) are two nuclear kinases involved different steps division. We have studied whether there is any functional connection between these kinases, which phosphorylate histone H3 Thr3 Ser10, respectively. VRK1 AURKB able to form a stable protein complex, represents only minor subpopulation each within...
Active therapeutic combinations, such as trabectedin and radiotherapy, offer potentially higher dimensional response in second-line treatment of advanced soft-tissue sarcomas. Dimensional can be relevant both for symptom relief survival.To assess the combined use radiotherapy treating patients with progressing metastatic sarcomas.Phase 1 this nonrandomized clinical trial followed classic 3 + design, planned at a fixed dose 30 Gy (3 Gy/d 10 days) infusion 1.3 mg/m2 starting dose, 1.5 level...
11502 Background: The immunogenic death caused by certain chemotherapy agents consists of molecular changes in tumor dying cells that stimulate immunogenicity and enhance antitumor effects. Doxorubicin is one validated drug related to death, mainly through calreticulin membrane translocation elicits signals as phagocytosis dendritic cells. Doxorubicin+pembrolizumab was explored a phase I/II trial treating patients with metastatic/unresectable sarcomas, achieving 22% PR, 59% SD, 19% PD, mPFS...
Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors demonstrated activity in terms of progression-free survival (PFS) advanced dedifferentiated liposarcoma (DD-LPS), a sarcoma with CDK4 amplification. overexpression is by far more common than amplification sarcomas it might be rational target for CDK inhibitors. Preclinical investigators this study found that overexpression, while not CDKN2A, was the most consistent predictive factor palbociclib efficacy sarcomas. Advanced adult-type...
Solitary fibrous tumor (SFT) is a rare, non-hereditary soft tissue sarcoma thought to originate from fibroblastic mesenchymal stem cells. The etiology of SFT be due an environmental intrachromosomal gene fusion between NGFI-A-binding protein 2 (NAB2) and signal transducer activator 6 (STAT6) genes on chromosome 12, wherein the activation domain STAT6 fused with DNA-binding NAB2 resulting in oncogenesis SFT. All NAB2-STAT6 variations discovered SFTs contain C-terminal transcript, thus can...
Purpose: Nilotinib plus doxorubicin showed to be synergistic regarding apoptosis in several sarcoma cell lines. A phase I/II trial was thus designed explore the feasibility of nilotinib as coadjuvant by inhibiting MRP-1/P-gp efflux activity. The I part study is presented here.Patients and Methods: 400 mg/12 hours administered fixed dose from day 1 6, on 5 each cycle. Three escalation levels for at 60, 65, 75 mg/m2 were planned. Cycles repeated every 3 weeks a total 4 cycles. Eligible...
Abstract HMGA1 is a structural epigenetic chromatin factor that has been associated with tumor progression and drug resistance. Here, we reported the prognostic/predictive value of for trabectedin in advanced soft-tissue sarcoma (STS) effect inhibiting or mTOR downstream pathway activity. The expression was assessed cohort 301 STS patients at mRNA (n = 133) protein level 272), by HTG EdgeSeq transcriptomics immunohistochemistry, respectively. silencing on activity gene profiling measured...
PURPOSE Doxorubicin, alongside a select group of cytotoxic agents, is capable inducing an adaptive immune response via well-established peculiar type tumor cell death called immunogenic (ICD). We hypothesize that combining doxorubicin and dacarbazine with nivolumab may enhance therapeutic efficacy by exerting synergy in the ICD circuit. hereby present phase Ib trial this combination. PATIENTS AND METHODS Patients advanced leiomyosarcoma anthracycline-naïve were eligible. The initial dose...
Abstract Background Herein, we present the results of phase 2 IMMUNOSARC study (NCT03277924), investigating sunitinib and nivolumab in adult patients with advanced bone sarcomas (BS). Methods Progressing a diagnosis BS were eligible. Treatment was comprised (37.5 mg/day on days 1–14, 25 afterword) plus (3 mg/kg every weeks). Primary end point progression‐free survival rate (PFSR) at 6 months based central radiology review. Secondary points overall (OS), response (ORR) by Response Evaluation...
Cancers, especially fusion oncoprotein (FO)-driven hematological cancers and sarcomas, often develop from a low number of key mutations. Solitary Fibrous Tumor (SFT) is rare mesenchymal tumor driven by the NAB2-STAT6 oncofusion gene. Currently, treatment options for SFT remain limited, with anti-angiogenic drugs providing only partial responses an average survival two years. To address this challenge, we constructed cell models harboring specific transcripts using CRISPR (Clustered Regularly...